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Background: Regadenoson, dipyridamole and adenosine are commonly used vasodilators in myocardial perfusion
imaging for the detection of obstructive coronary artery disease. There are few comparative studies of the
vasodilator properties of regadenoson, adenosine and dipyridamole in humans. The specific aim of this study was
to determine the relative potency of these three vasodilators by quantifying stress and rest myocardial perfusion in
humans using cardiovascular magnetic resonance (CMR).
Methods: Fifteen healthy normal volunteers, with Framingham score less than 1% underwent vasodilator stress
testing with regadenoson (400 μg bolus), dipyridamole (0.56 mg/kg) and adenosine (140 μg /kg/min) on separate
days. Rest perfusion imaging was performed initially. Twenty minutes later, stress imaging was performed at peak
vasodilation, i.e. 70 seconds after regadenoson, 4 minutes after dipyridamole infusion and between 3–4 minutes of
the adenosine infusion. Myocardial blood flow (MBF) in ml/min/g and myocardial perfusion reserve (MPR) were
quantified using a fully quantitative model constrained deconvolution.
Results: Regadenoson produced higher stress MBF than dipyridamole and adenosine (3.58 ± 0.58 vs. 2.81 ± 0.67 vs.
2.78 ± 0.61 ml/min/g, p = 0.0009 and p = 0.0008 respectively). Regadenoson had a much higher heart rate response
than adenosine and dipyridamole respectively (95 ± 11 vs. 76 ± 13 vs. 86 ± 12 beats/ minute) When stress MBF was
adjusted for heart rate, there were no differences between regadenoson and adenosine (37.8 ± 6 vs. 36.6 ± 4 μl/sec/g,
p = NS), but differences between regadenoson and dipyridamole persisted (37.8 ± 6 vs. 32.6 ± 5 μl/sec/g, p = 0.03). The
unadjusted MPR was higher with regadenoson (3.11 ± 0.63) when compared with adenosine (2.7 ± 0.61, p = 0.02) and
when compared with dipyridamole (2.61 ± 0.57, p = 0.04). Similar to stress MBF, these differences in MPR between
regadenoson and adenosine were abolished when adjusted for heart rate (2.04 ± 0.34 vs. 2.12 ± 0.27, p = NS), but
persisted between regadenoson and dipyridamole (2.04 ± 0.34 vs. 1.77 ± 0.33, p = 0.07) and between adenosine and
dipyridamole (2.12 ± 0.27 vs. 1.77 ± 0.33, p = 0.01).
Conclusions: Based on fully quantitative perfusion using CMR, regadenoson and adenosine have similar vasodilator
efficacy and are superior to dipyridamole.
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Regadenoson, dipyridamole and adenosine are com-
monly used, FDA approved vasodilators for the noninva-
sive detection of obstructive coronary artery disease (CAD)
using myocardial perfusion imaging [1,2]. Regadenoson is a
newer, selective adenosine 2A receptor agonist initially
studied in myocardial perfusion imaging with nuclear
scintigraphy techniques [3,4]. Regadenoson is a more
potent vasodilator than adenosine and exhibits selectivity
for the coronary circulation relative to the renal, periph-
eral and mesenteric circulation in animals [5]. Adenosine
is nonselective and causes negative chronotropic, dro-
motropic and inotropic effects via A1 receptors. It also
causes bronchospasm and mast cell degranulation via A3
receptors. In contrast, dipyridamole induces vasodilation
indirectly, by blocking adenosine reuptake and increasing
endogenous adenosine.
In animal studies, regadenoson was a more potent vaso-
dilator than adenosine. The higher median effective dose,
defined as the dose producing 50% of maximum effect
was 0.34 ± 0.08 μg/kg for regadenoson and 51 ± 15 μg/kg
for adenosine. The increase in CBF with regadenoson
reached 84 ± 5% of maximal reactive hyperemia. Both va-
sodilators had similar maximal increase in coronary blood
flow (CBF) [6] and produced similar hemodynamic effects
and biodistribution of radiotracers as assessed with nu-
clear perfusion imaging [7].
The hemodynamic effects of regadenoson have been
studied in humans by measuring the increase in the peak
coronary flow velocity (CFV) using intracoronary pulsed
Doppler. This dose ranging study, using intravenous
administration of 10-500 μg of regadenoson assessed the
increase in the average peak CFV in 34 human subjects.
The mean peak increases in CFV ± SD with intravenous
regadenoson at doses of 10, 30, 100, 300, 400, and
500 μg were 1.8 ± 0.57, 2.5 ± 0.54, 3.0 ± 0.61, 3.4 ± 0.77,
3.1 ± 0.52, and 3.1 ± 0.79 times respectively higher than
baseline [8]. A dose of 400 μg regadenoson was not inferior
compared to adenosine in the detection of the extent
and severity of perfusion defects [9]. However, compara-
tive studies of quantitative perfusion with regadenoson,
dipyridamole and adenosine have not been performed
in humans.
First pass perfusion using CMR is accurate in the de-
tection of coronary artery disease [10-15] and in the
quantification of MBF [16-19]. Until recently, dipyridamole
and adenosine have been commonly used in CMR per-
fusion imaging protocols. Regadenoson has desirable
factors such as bolus administration that can simplify
stress perfusion CMR.
The specific aim of this study was to compare the ef-
fectiveness of regadenoson vs. dipyridamole vs. adeno-
sine using first pass quantitative perfusion CMR in
healthy normal volunteers. We hypothesized that, ifregadenoson causes a significantly higher increase in
the stress MBF compared to adenosine or dipyrida-
mole, then quantitative perfusion CMR will be able to
demonstrate differences between these agents.
Methods
Study population
The inclusion criteria for volunteers were: absence of chest
pain for the past 6 months, no smoking history, and no
cardiac risk factors. Exclusion criteria were standard
CMR contradictions such as cerebral aneurysm clips,
metal in the eye, and implanted metallic devices.
Study design
All volunteers were asked to abstain from caffeinated
products for at least 24 hours. Caffeine levels were drawn
on the day of each CMR scan to document compliance.
The study design is shown below (Figure 1A, B and C).
Rest imaging was performed first followed by stress imaging
20 minutes later. Regadenoson was administered as a
400 mcg dose over 10 seconds, followed by a 10 ml saline
flush. Dipyridamole was given as a 0.56 mg/kg infusion
for 4 minutes and adenosine as a 140 mcg/kg infusion for
5–6 minutes. Stress imaging was performed at peak vaso-
dilation defined as 70 seconds after regadenoson bolus,
4 minutes after dipyridamole infusion, and 3–4 minutes
after the start of the adenosine infusion. This study
had institutional review board approval and all subjects
provided written informed consent.
The order of studies with a specific vasodilator was
not randomized. All volunteers underwent stress testing
with regadenoson, followed by dipyridamole and then
adenosine on different days. All studies were performed
between 8 am and noon. The average duration between
the regadenoson and dipyridamole scans was 18 days and
the duration between dipyridamole and the adenosine
scans was 67 days. Five of the original volunteers returned
for a fourth visit for interstudy reproducibility with
regadenoson. The average duration between the first scan
with regadenoson and the repeat scan was 54 days.
CMR protocol
All volunteers were scanned with a 1.5 T Siemens scanner
(Espree, Siemens Medical Solutions, Erlangen, Germany).
Rest and stress imaging was performed, each with
0.05 mmol/kg of gadolinium-DTPA (Magnevist, Berlex
Laboratories, Wayne, NJ, USA), diluted to provide injec-
tions of equal volumes and flushed with saline at 5 mL/sec
flow rate (Medrad, Indianola, PA, USA).
A saturation recovery-prepared steady state free preces-
sion sequence was used to acquire three slice locations
(base, mid, and apex) every R-R interval for a period lasting
60 heartbeats. Typical imaging parameters included a
saturation preparation pulse, readout excitation flip angle
Figure 1 A, B and C: study design using regadenoson,
dipyridamole and adenosine. Sixteen volunteers underwent stress
perfusion studies in three separate exams using regadenoson,
dipyridamole and adenosine. Gadolinium contrast is shown as Gd.
Minutes and seconds are shown as min and sec respectively.
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1085 Hz/pixel, acquisition matrix 128 × 80, field of
view 360 × 270 mm, slice thickness 8 mm, with parallel
imaging acceleration factor of 2. The acquisition shot
duration was 92 ms. A separate saturation preparation
pulse was used for each slice. The time per slice was
132 ms which included the saturation preparation
pulse, delay and imaging. A proton density-weighted
reference image was acquired to facilitate surface coil
intensity correction, at the beginning of perfusion im-
aging, using a small magnetization flip angle (8°) and
no saturation preparation pulse. For the arterial input
function (AIF) acquisition, only the mid slice was acquiredevery RR interval. A separate saturation prepared, low
resolution image with FLASH readout, acquisition
matrix 48 × 64, temporal resolution 60 ms was acquired at
the beginning of each RR interval for arterial input function
(AIF) assessment as described by Gatehouse et al [20]. This
was followed by the myocardial perfusion imaging whose
parameters have been described above.
Myocardial blood flow quantification
In healthy normal volunteers, the stress MBF is not
expected to have regional differences among the basal,
mid and apical segments. The apical slices were not
analyzed. Only the basal and mid slices were analyzed with
similar estimates of MBF. To conform to the commonly
reported mid-ventricular slice in studies of quantitative
myocardial perfusion, we have reported the results from
the mid ventricular slice only. The mid myocardial per-
fusion slice was divided into six radial sectors. Contours
of the left ventricular (LV) epicardial and endocardial
borders were manually traced on each image. Time-signal
intensity curves of myocardial regions of interest (ROIs)
were generated and analyzed using custom software written
in Interactive Data Language (Research Systems Inc
Boulder, CO, USA). The AIF was quantified by drawing
ROIs in the LV cavity in the low resolution images acquired
concurrently with myocardial perfusion images. In first-
pass perfusion imaging, the time-signal intensity measure-
ments within the heart reflect the contrast concentration
during the wash-in and wash-out of the bolus.
We used a modified Fermi function deconvolution
method to quantify MBF in ml/min/g and MPR as pre-
viously described by Hsu et al [17], except the AIF was
imaged using a dual sequence method as described by
Gatehouse et al [20]. MBF in each of the six sectors
were fit individually from the ROIs and then averaged
for every volunteer. None of the ROIs were discarded
due to poor fits.
The image analysts were not blinded to the stress
agent used. There were multiple steps in the workflow
including image processing for myocardial perfusion and
AIF assessment, and the MBF analysis which were done
in separate time periods.
Statistical analysis
Data was analyzed using MedCalc version. 11.6. All data
are presented as mean ± standard deviation. A sample
size of 15 in each group of normal volunteers was re-
quired to detect a 25% increase in resting MBF with
regadenoson, with an alpha of 0.05 and a power of 0.8.
Our first criterion for a better vasodilator was a higher
stress MBF. The next criterion was to observe an increase
in stress MBF on a per subject basis. Inter-observer, intra-
observer reproducibility and repeatability between two
studies were analyzed in 5 subjects using Bland-Altman
Table 1 Demographics of the study population
Characteristics Mean ± SD or percentage









Total- Cholesterol (mg/dl ± SD) 147 ± 38
LDL- Chol (mg/dl ± SD) 86 ± 35
HDL-Chol (mg/dl ± SD) 49 ± 17
Triglyceride (mg/dl ± SD) 62 ± 30
SD is defined as standard deviation, mg/dl as milligram/deciliter.
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to assess reproducibility.
Differences in absolute myocardial blood flow between
the three vasodilators were assessed using ANOVA with
repeated measures and with Bonferroni correction for
multiple comparisons. In addition, the myocardial blood
flow was adjusted for heart rate and compared between
the three drugs. Correlation between the heart rate and
stress myocardial blood flow was assessed using Spearman’s
correlation coefficient.Figure 2 First pass perfusion imaging and analysis of signal intensity
The first image is a proton density weighted image. The subsequent image
and subsequently myocardial perfusion. ROIs can be used to measure sign
The lower row shows time intensity curves of a single volunteer with regad
myocardium and the arterial input function during stress are shown as My
arbitrary units (A.U).Results
The rest and stress MBF for each of the three vasodilators
followed a normal distribution as confirmed with the
Kolmogorov-Smirnov test of normality.
The 16 healthy volunteers had a Framingham score
less than 1% by design and thus a very low risk profile
with respect to CAD as summarized in Table 1. None of
these subjects reported any prior history of chest pain
that would have warranted medical evaluation. Figure 2
shows typical time-signal intensity curves of a first-pass
perfusion CMR study using regadenoson, dipyridamole
and adenosine. All of the volunteers, except one had un-
detectable caffeine levels. This volunteer had a caffeine
level of 1.1 μg/ml on the day of adenosine stress imaging
and was excluded from the analysis. The final sample
size was 15 healthy volunteers.
Stress MBF (ml/min/g) was significantly higher for
regadenoson, 3.58 ± 0.58 when compared to dipyridamole,
2.81 ± 0.67, p = 0.0009, and adenosine, 2.78 ± 0.61,
p = 0.0008 (Figure 3A). No statistically significant dif-
ference in resting MBF between the three vasodilators
was noted (regadenoson, 1.21 ± 0.38, dipyridamole,
1.09 ± 0.22 and adenosine 1.04 ± 0.24, p = NS).
When stress MBF was adjusted for heart rate, there
were no differences between regadenoson and adeno-
sine (37.8 ± 6 vs. 36.6 ± 4 μl/sec/g, p = NS), but diffe-
rences between regadenoson and dipyridamole persisted.
(37.8 ± 6 vs. 32.6 ± 5 μl/sec/g, p = 0.03) as shown in
Figure 3B. Adenosine had higher MBF (36.6 ± 4 vs.
32.6 ± 5 μl/sec/g, p = 0.04) after adjusting for heart rate as. The upper row shows still frame images of the first pass perfusion.
s show the transit of contrast through the right ventricle, left ventricle
al intensity as a function of time to quantitatively analyze perfusion.
enoson, dipyridamole and adenosine. The time intensity curves of the
o-Stress and AIF-Stress respectively. Signal intensity is displayed as
Figure 3 Unadjusted and adjusted rest and stress MBF with all
three stress agents in 3A and 3B respectively. Regadenoson has
a statistically significant higher unadjusted stress MBF than
dipyridamole and adenosine. No difference in the unadjusted stress
MBF between dipyridamole and adenosine. No difference in the
resting MBF between all three agents is noted. However after
adjusting for heart rate, both regadenoson and adenosine have
similar stress MBF, which is higher than that of dipyridamole. Data in
the box plot are represented as mean ± standard error and the
whiskers represent the standard deviation.
Figure 4 Unadjusted and adjusted MPR with all three stress
agents in 4A and 4B respectively. Regadenoson has a statistically
significant higher unadjusted stress MPR than dipyridamole and
adenosine. However after adjusting for heart rate, both regadenoson
and adenosine have similar MPR, which is higher than that
of dipyridamole.
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major driver of the higher MBF response with regadenoson.
MPR was significantly higher with regadenoson than
dipyridamole (3.11 ± 0.62 vs. 2.61 ± 0.57, p = 0.04) and
adenosine (3.11 ± 0.62 vs. 2.7 ± 0.30, p = 0.02), as shown in
Figure 4A. No significant differences in rest, stress MBF and
the MPR was noted between dipyridamole and adenosine.
Similar to stress MBF, the differences in MPR between
regadenoson and adenosine were abolished when adjusted
for heart rate (2.04 ± 0.34 vs. 2.12 ± 0.27, p = NS). How-
ever differences between regadenoson and dipyridamole
persisted with a trend towards statistical significance
(2.04 ± 0.34 vs. 1.77 ± 0.33, p = 0.07) as shown in Figure 4B.
Adenosine had higher MPR than dipyridamole (2.12 ±
0.27 vs. 1.77 ± 0.33, p = 0.01) after adjusting for heart rate
as shown in Figure 4B.
The individual stress MBF with regadenoson, dipyri-
damole and adenosine on a per-subject basis is noted
in Figure 5. While there is a wide range of absoluteblood flow, 12 of 15 subjects had higher stress MBF
with regadenoson compared to adenosine as shown in
Figure 5A. Similarly, 11 of 15 subjects had higher stress
MBF with regadenoson compared to dipyridamole as
shown in Figure 5B. When dipyridamole was compared
with adenosine, 9 of 15 had higher MBFs with dipyridamole
as shown in Figure 5C.
There were no differences in the resting heart rate
between each of the three vasodilators (63 ± 12 vs. 59 ±
8 vs. 60 ± 9) for regadenoson, dipyridamole and adenosine
respectively. Regadenoson had a much higher heart rate
response than adenosine (95 ± 11 vs. 76 ± 13 beats/minute)
and dipyridamole (95 ± 11 vs. 86 ± 12 beats/minute). The
greatest increase in heart rate was noted with regadenoson
(31 ± 2.5 beats per minute), compared with dipyridamole
(27 ± 6, p = 0.05) and adenosine (16 ± 8, p = 0.0002) as
shown in Figure 6. Dipyridamole had a statistically
higher increase in heart rate when compared to adenosine
(p < 0.001). Mean change in systolic blood pressure (SBP)
was −4.8 ± 9 mmHg with regadenoson, -4.4 ± 13 mmHg
with dipyridamole and −0.7 ± 10 mmHg with adenosine.
Figure 5 Stress MBF on a per-subject basis between two drugs in 5A, B and C. Stress MBF with regadenoson and dipyridamole is noted in
5A. The 12/15subjects with a lower stress MBF response to dipyridamole when compared to regadenoson are shown in solid lines. Stress MBF
with regadenoson and adenosine is noted in 5B. The 11/15 subjects with a lower stress MBF response to adenosine when compared to
regadenoson are shown in solid lines. Stress MBF with dipyridamole and adenosine is noted 5C. 9/ 15 subjects had a higher MBF with
dipyridamole than with adenosine.
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9 mm Hg with regadenoson, -0.9 ± 7 mmHg with di-
pyridamole and −2.4 ± 7 mm Hg with adenosine. No
statistically significant differences in blood pressure
changes were found between these three vasodilators.
We tested the correlation of heart rate with MBF at
rest and with stress as shown in Figures 7A, B and C.
There is a good correlation between heart rate and res-
ting MBF (R = 0. 80, 0.62 and 0.87) for regadenoson, di-
pyridamole and adenosine respectively. Similarly there
was a modest correlation between the heart rate and
stress MBF (R = 0. 49, 0.58 and 0.90) for regadenoson,
dipyridamole and adenosine respectively. As shown in
Figure 7A and B, compared with dipyridamole, both
adenosine and regadenoson have higher MBF for similar
heart rates, ie the curve is shifted upward. However with
regadenoson, in addition to an upward shift the curve is
also shifted right ie. a higher heart rate responseFigure 6 Hemodynamic changes with regadenoson,
dipyridamole and adenosine. Compared to dipyridamole and
adenosine, regadenoson induced a larger increase in heart rate (HR) with
no difference in systolic or diastolic blood pressure (SBP, DBP) reduction.(Figure 7B and C). Such an upward and rightward shift
with regadenoson is noted in comparison with adenosine
as well, highlighting the higher heart rate response with
regadenoson. This higher heart rate response with
regadenoson is not explained entirely by the decrease in
systolic blood pressure. The correlation between the
change in heart rate with the change in systolic BP for
regadenoson is poor, R = 0.08. This suggests a direct
adrenergic effect on heart rate, which is substantiated in
animal studies [21].
Measurements of resting and stress MBF in 5 subjects
were analyzed by two operators to assess for both inter-
observer and intra-observer reproducibility. Similarly
resting and stress MBF were tested for repeatability with
a second study using the same vasodilator. The Bland-
Altman analysis plots showed all measurements within
the 2SD range suggesting good inter- and intra-observer
reproducibility (Figure 8). With the exception of one
subject, rest and stress MBFs for the repeat study were
within the 2SD range suggesting good day to day repea-
tability (Figure 8). In addition the coefficients of va-
riation for rest MBF were 0.17, 0.15 and 0.15 and for
stress MBF with regadenoson were 0.22, 0.18 and
0.19 for Observer 1, Observer 1_Repeat and Observer
2 respectively.
Discussion
In this study of vasodilator efficacy among three FDA
approved vasodilators, regadenoson had the highest
stress MBF response when compared with dipyridamole
and adenosine. However this is mediated primarily by a
higher heart rate response with regadenoson. When ad-
justed for heart rate, regadenoson and adenosine have
similar stress MBF and MPR, but both drugs have higher
MBF and MPR than dipyridamole. To the best of our
Figure 7 A, B and C: correlation between heart rate and MBF is
shown in a two-drug comparison. As shown in 7A, adenosine has
a parallel upward shift ie. a higher MBF for the same heart rate,
compared to dipyridamole. In contrast, regadenoson has an upward
and rightward shift i.e. higher MBF and heart rate when compared
to dipyridamole and adenosine as shown in 7B and C respectively.
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vasodilator properties in the same set of volunteers with
the three commonly used vasodilators using quantitative
first pass perfusion with CMR.
We expected a higher efficacy with regadenoson due
to the selectivity of A2A receptors than adenosine with
its nonselective action on the A1 and A3 receptors. The
superior vasodilator properties of regadenoson and
adenosine over dipyridamole may be explained by its
direct action as an adenosine receptor agonist, in
contrast to dipyridamole which causes vasodilation in-
directly by increasing cellular levels of adenosine. Asshown in the correlation between heart rate and MBF
for each of the vasodilators, when compared with dipyri-
damole, adenosine has higher MBF for a given heart
rate. In contrast, when compared with dipyridamole and
adenosine, regadenoson has an even higher MBF and
heart rate response i.e. upward and rightward shift. This
increase in heart rate is not entirely explained by the
changes in blood pressure and there might be a com-
ponent of direct sympathetic activation causing this
tachycardia. This mechanism has been substantiated in
animal studies by Dhalla et al [21]. This higher heart rate
response might be beneficial in the context of stress
testing where increased demand can help identify ische-
mia. In clinical practice, these heart rate effects of rega-
denoson are transient and resolve by the time late
gadolinium enhancement (LGE) imaging is performed
(heart rate with regadenoson pre- LGE was 64 ± 12
beats per minute similar to resting heart rate, 63 ± 12
beats per minute), with no effect on subsequent image
quality.
Our analysis of perfusion slices was limited to the mid
myocardium. A recent study of quantitative perfusion in
normal volunteers suggested that there was a modest
increase in stress MBF in diastole compared to systole
[22]. For quality assurance reasons, we analyzed the
timing of slices within the cardiac cycle using the ap-
proach described by Feinstein et al [23]. Since only one
AIF slice was acquired for each RR interval (for base,
mid and apical slices) the prepulse delay was not signifi-
cant. With regadenoson, which had the highest heart
rate, mean of 95, the RR interval was 632 ms. The time
per slice for the AIF acquisition was 60 ms, and the
myocardial perfusion acquisition was 132 ms. Therefore,
the AIF, base and mid slices could be acquired in
324 ms which is about 50% of the cardiac cycle, with the
mean heart rate of 95 during stress. As one approaches
the HR of 100, systole and diastole are similar in du-
ration. The basal and mid slices were typically systolic,
while the apical slice was diastolic (data not shown).The
timing of the mid ventricular slice acquisition with all
three vasodilators was in systole. Thus, the differences in
stress MBF represent the differences in vasodilation
between the three agents and not due to varying cardiac
phase.
The impact of differences on the sensitivity and speci-
ficity of detecting coronary artery disease is limited to
studies using SPECT perfusion comparing dipyridamole,
adenosine and exercise stress with conflicting data [24-26].
ADVANCE-MPI (ADenoscan Versus regAdenosoN Com-
parative Evaluation for Myocardial Perfusion Imaging), a
phase 3 multicenter international trial, showed fair con-
cordance (chi-square coefficient of 0.63) between rega-
denoson and adenosine for detection of reversible
perfusion defects with 99mTc-MIBI or 99mTc-Tetrofosmin
Figure 8 Bland-Altman plots show good inter-observer reproducibility, intra-observer reproducibility and inter-study repeatability in
5 subjects.
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even in comparisons between adenosine- adenosine scans
(chi-square coefficient of 0.64) and the large number
(60%) of normal scans [3,27]. Dibella et al. performed a
direct comparison of myocardial perfusion reserve with
adenosine and regadenoson in 8 subjects without ischemia
[28]. No difference in the MPR was noted between adeno-
sine (2.3 ± 0.9) and regadenoson (2.4 ± 0.9). Our findings
are concordant with this study with similar values of MPR
with adenosine and regadenoson.
While there are no differences in efficacy, regadenoson
has a relative ease of administration as a rapid bolus,
with a single intravenous line placement in contrast to
adenosine which requires two intravenous lines and a
6 minute infusion. Regadenoson has a good safety profile
in patients. In clinical studies, there was no incidence of
atrioventricular block [3] and bronchospasm in patients
with mild or moderate chronic obstructive pulmonary
disease [29,30].
Limitations
The study population consists predominantly of young,
healthy male volunteers. We selected this population so
we can test the efficacy of these three drugs. We ac-
knowledge that response of patients to vasodilators is
influenced not only by coronary artery disease but con-
comitant risk factors [31]. Patients might have different
normal ranges of blood flow responses than young
healthy volunteers. Such data will be helpful in the inter-
pretation of quantitative perfusion.
The protocol used in this study was rest-stress imaging
which is different from currently used protocols. We
chose this study design due to concerns about residual
vasodilation that we encountered in clinical practice and
substantiated by Bhave et al [32]. This paper suggested
inadequate recovery to rest blood flow with regadenoson
i.e. residual vasodilation. The rest-stress study design
avoids the problem of residual vasodilation and provides
the best assessment of the vasodilator effects of thedrugs in a study population, not expected to have LGE
and heterogeneous contrast on board.
Conclusions
Using quantitative first pass perfusion CMR in young,
healthy normal volunteers, we showed that regadenoson
and adenosine have similar efficacy and are a better
vasodilator than dipyridamole.
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